Prediction of Anti-cancer Nanotherapy Efficacy by Imaging

DSpace/Manakin Repository

Prediction of Anti-cancer Nanotherapy Efficacy by Imaging

Citable link to this page


Title: Prediction of Anti-cancer Nanotherapy Efficacy by Imaging
Author: Miller, Miles A.; Arlauckas, Sean; Weissleder, Ralph

Note: Order does not necessarily reflect citation order of authors.

Citation: Miller, Miles A., Sean Arlauckas, and Ralph Weissleder. 2017. “Prediction of Anti-cancer Nanotherapy Efficacy by Imaging.” Nanotheranostics 1 (3): 296-312. doi:10.7150/ntno.20564.
Full Text & Related Files:
Abstract: Anticancer nanotherapeutics have shown mixed results in clinical trials, raising the questions of whether imaging should be used to i) identify patients with a higher likelihood of nanoparticle accumulation, ii) assess nanotherapeutic efficacy before traditional measures show response, and iii) guide adjuvant treatments to enhance therapeutic nanoparticle (TNP) delivery. Here we review the use of a clinically approved MRI nanoparticle (ferumoxytol, FMX) to predict TNP delivery and efficacy. It is becoming increasingly apparent that nanoparticles used for imaging, despite clearly distinct physicochemical properties, often co-localize with TNP in tumors. This evidence offers the possibility of using FMX as a generic “companion diagnostic” nanoparticle for multiple TNP formulations, thus potentially allowing many of the complex regulatory and cost challenges of other approaches to be avoided.
Published Version: doi:10.7150/ntno.20564
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search